Allot (NASDAQ:ALLT) reported quarterly losses of $(0.11) per share. This is a 175 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $32.77 million which beat the analyst consensus estimate of $32.46 million by 0.96 percent. This is a 7.13 percent decrease over sales of $35.29 million the same period last year.
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
